Teva Pharmaceutical Industries Limited (NYSE:TEVA) Rating Lowered to Market Perform at Sanford C. Bernstein

Sanford C. Bernstein cut shares of Teva Pharmaceutical Industries Limited (NYSE:TEVA) from an outperform rating to a market perform rating in a research report released on Friday, Marketbeat.com reports.

Several other research analysts have also recently issued reports on the company. Zacks Investment Research raised Teva Pharmaceutical Industries Limited from a sell rating to a hold rating in a research report on Monday, April 17th. Deutsche Bank AG lowered their price objective on Teva Pharmaceutical Industries Limited from $45.00 to $43.00 and set a buy rating on the stock in a research report on Friday, May 12th. Vetr raised Teva Pharmaceutical Industries Limited from a buy rating to a strong-buy rating and set a $37.48 price objective on the stock in a research report on Tuesday, April 11th. Citigroup Inc. lowered their price objective on Teva Pharmaceutical Industries Limited from $47.00 to $42.00 and set a buy rating on the stock in a research report on Tuesday, April 25th. Finally, Royal Bank Of Canada reaffirmed an outperform rating and set a $38.00 price objective (down from $42.00) on shares of Teva Pharmaceutical Industries Limited in a research report on Monday, May 15th. One equities research analyst has rated the stock with a sell rating, twenty-two have issued a hold rating, seven have issued a buy rating and one has assigned a strong buy rating to the stock. The company presently has a consensus rating of Hold and a consensus price target of $39.19.

Shares of Teva Pharmaceutical Industries Limited (NYSE TEVA) opened at 18.59 on Friday. Teva Pharmaceutical Industries Limited has a 52 week low of $18.50 and a 52 week high of $55.45. The company has a 50-day moving average price of $32.05 and a 200-day moving average price of $32.28. The company has a market capitalization of $18.89 billion, a PE ratio of 238.33 and a beta of 0.46.

Teva Pharmaceutical Industries Limited (NYSE:TEVA) last announced its earnings results on Thursday, August 3rd. The company reported $0.99 earnings per share (EPS) for the quarter, missing the consensus estimate of $1.06 by $0.07. The firm had revenue of $5.69 billion during the quarter, compared to analysts’ expectations of $5.72 billion. Teva Pharmaceutical Industries Limited had a positive return on equity of 15.96% and a negative net margin of 25.18%. The company’s revenue for the quarter was up 12.9% on a year-over-year basis. During the same period in the previous year, the business posted $1.25 earnings per share. Analysts predict that Teva Pharmaceutical Industries Limited will post $4.44 earnings per share for the current year.

COPYRIGHT VIOLATION NOTICE: This article was originally published by Markets Daily and is the property of of Markets Daily. If you are reading this article on another publication, it was illegally stolen and republished in violation of United States & international copyright and trademark law. The correct version of this article can be read at https://www.themarketsdaily.com/2017/08/08/teva-pharmaceutical-industries-limited-nyseteva-rating-lowered-to-market-perform-at-sanford-c-bernstein.html.

The company also recently disclosed a quarterly dividend, which will be paid on Thursday, September 14th. Shareholders of record on Tuesday, August 29th will be paid a $0.085 dividend. This represents a $0.34 dividend on an annualized basis and a yield of 1.83%. The ex-dividend date of this dividend is Friday, August 25th. Teva Pharmaceutical Industries Limited’s payout ratio is -18.95%.

Several institutional investors have recently added to or reduced their stakes in the stock. Prudential Financial Inc. increased its position in Teva Pharmaceutical Industries Limited by 0.9% in the second quarter. Prudential Financial Inc. now owns 77,973 shares of the company’s stock valued at $2,590,000 after buying an additional 730 shares in the last quarter. GHP Investment Advisors Inc. increased its position in Teva Pharmaceutical Industries Limited by 29.4% in the second quarter. GHP Investment Advisors Inc. now owns 13,353 shares of the company’s stock valued at $444,000 after buying an additional 3,030 shares in the last quarter. American Century Companies Inc. increased its position in Teva Pharmaceutical Industries Limited by 11.4% in the second quarter. American Century Companies Inc. now owns 1,996,395 shares of the company’s stock valued at $66,320,000 after buying an additional 204,688 shares in the last quarter. Point View Wealth Management Inc. increased its position in Teva Pharmaceutical Industries Limited by 13.7% in the second quarter. Point View Wealth Management Inc. now owns 44,406 shares of the company’s stock valued at $1,475,000 after buying an additional 5,343 shares in the last quarter. Finally, First National Trust Co. increased its position in Teva Pharmaceutical Industries Limited by 6.7% in the second quarter. First National Trust Co. now owns 8,878 shares of the company’s stock valued at $295,000 after buying an additional 555 shares in the last quarter. 56.27% of the stock is currently owned by hedge funds and other institutional investors.

Teva Pharmaceutical Industries Limited Company Profile

Teva Pharmaceutical Industries Limited is a pharmaceutical company. The Company is engaged in developing, producing and marketing generic medicines and a portfolio of specialty medicines. The Company operates through two segments: Generic medicines and Specialty medicines. The Company develops, manufactures and sells generic medicines in a range of dosage forms, including tablets, capsules, injectables, inhalants, liquids, ointments and creams.

Analyst Recommendations for Teva Pharmaceutical Industries Limited (NYSE:TEVA)

Receive News & Ratings for Teva Pharmaceutical Industries Limited Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Teva Pharmaceutical Industries Limited and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply